Bezafibrate
Mechanism :
Bezafibrate is a lipid lowering drug.
Indication :
- Hypercholesterolemia
- Dyslipidemia
Contraindications :
Renal and hepatic dysfunction, and gall bladder disease.
Dosing :
Oral:
200 mg/day in adolescents. Very limited use in children.
Adverse Effect :
Gastrointestinal, nausea, anorexia, gastric pain; headache, pruritus, urticaria, myopathy.
Interaction :
Warfarin: Enhanced effect.
HMG-COA Reductase Inhibitors: Increased risk of rhabdomyolysis.
Bile Acid Sequestrants: Elevation in liver enzymes.
Renal Dose :
Dose in Renal Impairment GFR (mL/min)
| 40-60 | 400 mg daily |
| 15-40 | 200 mg every 24–48 hours |
| <15 | Avoid |
Dose in Patients undergoing Renal Replacement Therapies
| CAPD | Not dialysed. 200 mg every 72 hours |
| HD | Not dialysed. 200 mg every 72 hours |
| HDF/High flux | Unknown dialysability. 200 mg every 72 hours |
| CAV/VVHD | Unknown dialysability. Dose as in GFR=15–40 mL/min |
Hepatic Dose :
Avoid use in severe hepatic impairment.